

Review Article

Lactobacillus rhamnosus Interferes with *Candida albicans* Adherence and Biofilm Formation: A Potential Alternative Treatment of Candidiasis

Ribeiro FC¹, Iglesias MC², Barros PP¹, Santos SSF², Jorge AOC¹ and Leão MVP^{2,3*}

¹Department of Biosciences and Oral Diagnosis, Sao Paulo State University/UNESP, Brazil

²Bioscience Basic Institute, University of Taubate, Bom Conselho, Taubate, SP, Brazil

³School of Medical Sciences of São José dos Campos, Brazil

*Corresponding author: Leão MVP, School of Medical Sciences of São José dos Campos, Humanitas, São José dos Campos, Brazil

Received: March 19, 2021; Accepted: April 24, 2021;

Published: May 01, 2021

Abstract

The objective of the present study was to evaluate the ability of *Lactobacillus rhamnosus*, on different preparations (living lactobacilli, dead by heat lactobacilli and supernatant of lactobacilli suspension), to interfere with *Candida albicans* adherence to epithelial cells and biofilm formation. The results showed a reduction of 66.2% in the number of *Candida* cells adhered to epithelial cells, when the suspension of living *L. rhamnosus* was used. On the same way, this suspension reduced the *in vitro* biofilm formation by *C. albicans*. In conclusion, the suspension with living cells of *L. rhamnosus* was able to reduce the ability of *C. albicans* to adhere on epithelial cells and to form biofilm, suggesting a potential use of this probiotic bacteria as a therapeutic agent in candidiasis.

Keywords: Biofilm; *Candida*; *Lactobacillus*; Adherence; Probiotic

Introduction

With large utilization of antifungal to control *Candida* infections, several species have become resistant to drugs, especially those of the azole class. This resistance profile changes with the species and the strain due to the different mechanisms of resistance and also through the exposition time and drug concentration [1-3].

On the attempt to find new approaches of candidiasis treatment or improve the already existing ones, studies are being done in order to develop alternative methods to reduce fungal infections, or adjuvant therapies to induce better effects [4-6].

In literature, it has been reported that different *Lactobacillus* strains, with probiotic properties, are able to interfere with *C. albicans* colonization and/or infection [7-9]. *Lactobacillus* can inhibit *Candida* virulence factors, as germ tube, yeast adherence and hyphae and biofilm formation, leaving this yeast more susceptible to immune system action [10-13]. *Lactobacillus* can also change the sensitivity profile of *C. albicans* to antifungal, making them more susceptible to the treatment [14].

In this context, the present work aimed to study the ability of *Lactobacillus rhamnosus* LL0011 or only its products to inhibit *C. albicans* adherence to epithelial cells and biofilm formation.

Materials and Methods

Microorganisms

Lactobacillus rhamnosus LL0011 (Cefar Diagnóstica, São Paulo, Brasil) was plated on agar Man-Rogosa-Shape (MRS-Oxoid, Basingstoke, Hampshire, England) and cultivated on 37°C in 5% of CO₂ for 48 hours. After this time, three preparations were obtained: SpL - living lactobacilli cells, constituted of 10⁷ cells/mL of sterile saline, standardized in spectrophotometer at 530 nm; SpLA - dead by heat lactobacilli (SpLautoclaved by 15 min); SnLA - supernatant of SpLA.

C. albicans ATCC 18804 was grown in Sabouraud dextrose Agar (Difco, Detroit, USA), incubated at 37°C for 24h.

Adherence to oral epithelial cells assay

Epithelial cells from oral mucosa were obtained by four volunteers (same sanguine type, O group of the ABO system), through slight scraping of the mucosa, using disposable and sterilized wooden spatula. The obtained cells were placed in a sterilized tube with 2 mL of PBS, obtaining an epithelial cells pool that were washed three times with sterilized PBS on centrifugation on 1800 X g by 5 minutes each. After the washing, the deposit was resuspended until the obtaining of 10⁵ cells per mL, counted on Neubauer chamber. After the padronization of epithelial cells (described above) in the same tube was added *C. albicans* suspension of 10⁶ cells/mL of sterile saline, standardized in spectrophotometer at 530 nm, and the different preparations of *L. rhamnosus* (SpL, SpLA, SnLA) or saline (negative control). The tubes were incubated for 4 hrs at 37°C with 5% of CO₂. After 4 hrs the cells were washed and a total of one hundred cells were counted for each experiment.

Biofilm assay

To the formation of the biofilm was utilized 96 wells plate. In each plate were pipetted 200 µL of suspension of *C. albicans* prepared by YNB, the plate was incubated in agitation of 37°C by 120 minutes to the adherence initial phase. Completing this period, the suspensions were removed from the wells, which were washed on 200 µL of sterile saline solution. Afterwards, 100 µL of YNB improved with 100 mM of glucose were added to the wells plus 100 µL of each suspension of *L. rhamnosus* (SpL, SpLA ou SnLA) or saline solution (control). The plate was incubated to 37°C for 48 hours on agitation, changing the broth each 24 hours.

After 48 hours the biofilms were washed three times with saline solution, and detached using an ultrasonic homogenizer (Sonics Vibra-Cell VCX 130) with the potency of 50 W by 30s. From this




Figure 1: The counting of adhered *C. albicans* on epithelial cells, on the absence or presence of different suspensions of *L. rhamnosus* (SpL, SpLA e SnLA). Kruskal-Wallis test and post Dunn multiple comparison test was used. ***Candida* vs. *Candida* + SnLA** – $p = 0.5380$; ***Candida* vs. *Candida* + SpLA** – $p = 0.0002$; ***Candida* vs. *Candida* + SpL** – $p < 0.0001$. (SpL - living lactobacilli cells; SpLA - dead by heat lactobacilli (autoclaved by 15 min); SnLA - supernatant of lactobacilli suspension dead by heat).

solution, serial dilutions were obtained, plated in agar Sabouraud dextrose and incubated at 37°C for 48 hours, for counting of CFU/mL of *C. albicans*.

Results

In the adherence assay, it was observed that in the presence of living *L. rhamnosus* (SpL) there was a significant decrease (66.2%) in the adherence of *C. albicans* when compared with control (saline). Similar, but lower, results were observed when the SpLA was used, with 24.54% of reduction. However, the suspension containing only the supernatant of *L. rhamnosus* wasn't able to inhibit *C. albicans* adherence (Figure 1).

The biofilm results showed that when the SpL was used, a significant reduction ($p=0,036$) in the CFU/mL of *C. albicans* from the biofilm was observed. The other suspensions also have a slight reduction on *C. albicans* biofilm formation, however with no statistical significance when compared to the control (Figure 2).

Discussion

In this study we evaluated the anti-*Candida* potential of three different *L. rhamnosus* LL0011 suspensions against *C. albicans* on epithelial cells adherence and biofilm formation inhibition. Our data showed that presence of the *L. rhamnosus*, dead or alive, interfered on the adherence of *C. albicans* to the epithelial cell of oral mucosa, meanwhile when the SnLA was used, we could not note a reduction on *C. albicans* adherence. This data suggests that whole cell of *L. rhamnosus* or its structural molecules, but not its metabolites, are able to inhibit the *C. albicans* adherence. In the literature, some studies have been established the effects of *Lactobacillus* on pathogenic microorganism adhesion, especially on yeast of the genus *Candida*, and the mechanisms involved are related to exclusion, competition for receptors sites and displacement of adhesion [15-17]. It seems that some molecules presented on *Lactobacillus* cells, as well as biosurfactants, have the property of changing the surface tension of the medium displaying an anti-adhesive effect [8,18].

Many probiotics used on dairy products are composed of live lactobacilli. Their development presents a challenge for industrial production, since, the industry need a suitable technology and parameters that involve the viability and the stability of the




Figure 2: *C. albicans* CFU/mL counts from biofilms formed on the absence or presence of different suspensions of *L. rhamnosus* (SpL, SpLA e SnLA). Student's t test was used to compare the control group with the experimental groups. **Control vs. SnLA** – $p = 0.1321$; **Control vs. SpLA** – $p = 0.3349$; **Control vs. SpL** – $p = 0.0365$ (Control - *C. albicans* alone; SpL - living lactobacilli cells; SpLA - dead by heat lactobacilli (autoclaved by 15 min); SnLA - supernatant of lactobacilli suspension dead by heat).

microorganisms (stress tolerance during processing and storage of the product) [19]. In this study, the suspension containing *L. rhamnosus* dead by heat also showed an antagonist effects on *C. albicans* adherence and this characteristic is extremely interesting for its use in probiotic products. Since the microorganisms are dead, the product becomes more stable and viable, simplifying various industrial processes generating lower costs for its production, and bringing more benefits to its consumers.

The formation of biofilm is one of the most important virulence factors of *C. albicans*, since this factor is intimately related to the pathogenicity, providing bigger resistance to the host immune system and the action of antifungal. Our results showed that only the suspension containing the live *L. rhamnosus* was able to significantly reduce the *C. albicans* biofilm formation. The heat killing and the supernatant free-cells suspensions of *L. rhamnosus* presented a slight reduction on the biofilm; however they do not show statistical difference.

The *C. albicans* biofilm inhibition can occur on different phases of the biofilm formation, as adherence, initial colonization or on the maturation phase. This inhibition seems to differ depending on *Lactobacillus* strains used, once some species have better results on initial colonization phase and others on the other phases of the biofilm formation [20-22]. In the present work, since the adherence phase was on absence of lactobacilli, the results point to a mechanism of action of *L. rhamnosus* involving destructuring of biofilm or by the consumption of nutrients [22].

The first step in the pathogenesis of *C. albicans* is its ability to adhere on biotic (e.g. tissues) and abiotic surfaces (e.g. catheters), allowing the colonization in a specific niche and starting the infection process [17]. The results obtained on the present work show a significant inhibition of *C. albicans* both on adherence to epithelial cells and abiotic surfaces. This is a very promising result, which leads the possibility that *L. rhamnosus* can be used as a therapy to inhibit infections caused by *C. albicans* both in mucous membranes and from devices that allow biofilm formation.

Conclusion

Thus, the present study demonstrates that the suspension of living *L. rhamnosus* was able to inhibit the adherence of *C. albicans*

epithelial cells from oral mucosa and also capable to inhibiting and reducing the *C. albicans* growing on biofilm. Our study opens the perspective that *L. rhamnosus* LL0011 can be an interestingly strain to be used in future therapeutics studies against *C. albicans*.

References

1. Pristov KE, Ghannoum MA. Resistance of *Candida* to azoles and echinocandins worldwide. *Clin Microbiol Infect*. 2019; 25: 792-798.
2. Teo JQM, Lee SJY, Tan AL, Lim RSM, Cai Y, Lim TP, et al. Molecular mechanisms of azole resistance in *Candida* bloodstream isolates. *BMC Infect Dis*. 2019; 19: 1-4.
3. Prasad R, Nair R, Banerjee A. Multidrug transporters of *Candida* species in clinical azole resistance. *Fungal Genet Biol*. 2019; 132: 103252.
4. Scorzoni L, de Menezes RT, Pereira TC, Oliveira PS, Ribeiro F de C, Santos EL de S, et al. Antifungal and anti-biofilm effect of the calcium channel blocker verapamil on non-albicans *Candida* species. *An Acad Bras Cienc*. 2020; 92: 1-14.
5. Rossoni RD, de Barros PP, Mendonça I do C, Medina RP, Silva DHS, Fuchs BB, et al. The Postbiotic Activity of *Lactobacillus paracasei* 28.4 Against *Candida auris*. *Front Cell Infect Microbiol*. 2020; 10: 397.
6. de Barros PP, Rossoni RD, Ribeiro F de C, Silva MP, de Souza CM, Jorge AOC, et al. Two sporulated *Bacillus* enhance immunity in *Galleria mellonella* protecting against *Candida albicans*. *Microb Pathog*. 2019; 132: 335-42.
7. Santos RB, Scorzoni L, Namba AM, Rossoni RD, Jorge AOC, Junqueira JC. *Lactobacillus* species increase the survival of *Galleria mellonella* infected with *Candida albicans* and non-albicans *Candida* clinical isolates. *Med Mycol*. 2019; 57: 391-394.
8. Santos C, Ramos França Y, Duarte Lima Campos C, Quaresma Bomfim MR, Oliveira Melo B, Assunção Holanda R, et al. Antifungal and antivirulence activity of vaginal *Lactobacillus* spp. Products against *Candida* vaginal isolates. *Pathogens*. 2019; 8: 150.
9. de Barros PP, Scorzoni L, Ribeiro F de C, Fugisaki LR de O, Fuchs BB, Mylonakis E, et al. *Lactobacillus paracasei* 28.4 reduces in vitro hyphae formation of *Candida albicans* and prevents the filamentation in an experimental model of *Caenorhabditis elegans*. *Microb Pathog*. 2018; 117: 80-87.
10. Vilela SFG, Barbosa JO, Rossoni RD, Santos JD, Prata MCA, Anbinder AL, et al. *Lactobacillus acidophilus* ATCC 4356 inhibits biofilm formation by *C. Albicans* and attenuates the experimental candidiasis in *Galleria mellonella*. *Virulence*. 2015; 6: 29-39.
11. de Oliveira FE, Rossoni RD, de Barros PP, Begnini BE, Junqueira JC, Jorge AOC, et al. Immunomodulatory effects and anti-*Candida* activity of lactobacilli in macrophages and in invertebrate model of *Galleria mellonella*. *Microb Pathog*. 2017; 110: 603-611.
12. Matsuda Y, Cho O, Sugita T. Culture supernatants of *Lactobacillus gasseri* and *L. Crispatus* inhibit *Candida albicans* biofilm formation and adhesion to hela cells. *Mycopathologia*. 2018; 183: 691-700.
13. Allonsius CN, Vandenheuvel D, Oerlemans EFM, Petrova MI, Donders GGG, Cos P, et al. Inhibition of *Candida albicans* morphogenesis by chitinase from *Lactobacillus rhamnosus* GG. *Sci Rep*. 2019; 9: 1-12.
14. De Oliveira JR, De Aguiar Almeida RB, Das Graças Figueiredo Vilela P, De Oliveira FE, Da Rocha RF, Jorge AOC, et al. Control of microorganisms of oral health interest with *Arctium lappa* L. (burdock) extract non-cytotoxic to cell culture of macrophages (RAW 264.7). *Arch Oral Biol*. 2014; 59: 808-814.
15. Verdenelli MC, Coman MM, Cecchini C, Silvi S, Orpianesi C, Cresci A. Evaluation of antipathogenic activity and adherence properties of human *Lactobacillus* strains for vaginal formulations. *J Appl Microbiol*. 2014; 116: 1297-1307.
16. Poupet C, Saraoui T, Veisseire P, Bonnet M, Dausset C, Gachinat M, et al. *Lactobacillus rhamnosus* Lcr35 as an effective treatment for preventing *Candida albicans* infection in the invertebrate model *Caenorhabditis elegans*: First mechanistic insights. *PLoS One*. 2019; 14: e0216184.
17. Ribeiro FC, Rossoni RD, de Barros PP, Santos JD, Fugisaki LRO, Leão MPV, et al. Action mechanisms of probiotics on *Candida* spp. and candidiasis prevention: an update. *J Appl Microbiol*. 2020; 129: 175-185.
18. De Gregorio PR, Parolin C, Abruzzo A, Luppi B, Protti M, Mercolini L, et al. Biosurfactant from vaginal *Lactobacillus crispatus* BC1 as a promising agent to interfere with *Candida* adhesion. *Microb Cell Fact*. 2020; 19: 1-16.
19. Sarao LK, Arora M. Probiotics, prebiotics, and microencapsulation: A review. *Crit Rev Food Sci Nutr*. 2017; 57: 344-371.
20. Matsubara VH, Wang Y, Bandara HMHN, Mayer MPA, Samaranayake LP. Probiotic lactobacilli inhibit early stages of *Candida albicans* biofilm development by reducing their growth, cell adhesion, and filamentation. *Appl Microbiol Biotechnol*. 2016; 100: 6415-6426.
21. Son S, Jeon H, Yang S, Lee N, Paik H. *In vitro* characterization of *Lactobacillus brevis* KU15006, an isolate from kimchi, reveals anti-adhesion activity against foodborne pathogens and antidiabetic properties. *Microb Pathog*. 2017; 112: 135-141.
22. de Camargo Ribeiro F, Junqueira JC, dos Santos JD, de Barros PP, Rossoni RD, Shukla S, et al. Development of probiotic formulations for oral candidiasis prevention: Gellan Gum as a Carrier to Deliver *Lactobacillus paracasei* 28.4. *Antimicrob Agents Chemother*. 2020; 64: e02323-19.